Tonix's lead drug fails PhI­II again, send­ing stock even clos­er to ze­ro

When lit­tle Tonix Phar­ma­ceu­ti­cals re­vealed last Ju­ly that its lead drug failed an in­ter­im analy­sis in fi­bromyal­gia — so much so that out­side da­ta mon­i­tors rec­om­mend­ed halt­ing the tri­al it would un­like­ly pass muster — the com­pa­ny de­cid­ed to go ahead and fol­low pa­tients al­ready on the drug.

So it’s lit­tle sur­prise that TNX-102 flat out failed the fi­nal analy­sis of the Phase III RAL­LY study too, miss­ing sta­tis­ti­cal sig­nif­i­cance over place­bo on the pri­ma­ry end­point of re­duc­tion in dai­ly pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER